Enveric Biosciences (ENVB) Share-based Compensation (2015 - 2026)
Enveric Biosciences (ENVB) posted Share-based Compensation of $924217.0 for Q1 2026, up 257.65% sequentially from -$586229.0 in Q4 2025, and up 105645.65% YoY from N/an in Q1 2025.
Enveric Biosciences (ENVB) Share-based Compensation (2015 - 2026) Analysis & Trends
Enveric Biosciences has reported Share-based Compensation for 9 years, with the latest figure at $924217.0 in Q1 2026.
- Quarterly Share-based Compensation rose 105645.65% year-over-year to $924217.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $924217.0 (down 17.38% YoY) and the FY2025 annual result came in at $1.0 million, down 31.39% from the prior year.
- Share-based Compensation advanced to $924217.0 in Q1 2026 per ENVB's latest filing, from -$586229.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $924217.0 in Q1 2026 and troughed at -$586229.0 in Q4 2025.
- A 5-year average of $416699.2 and a median of $379377.0 in 2024 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2025 and 2026: Share-based Compensation plunged 254.52% in 2025, then soared 105645.65% in 2026.
- Over 5 years, Share-based Compensation stood at $529372.0 in 2022, then sank by 31.1% to $364728.0 in 2023, then gained by 4.02% to $379377.0 in 2024, then slumped by 254.52% to -$586229.0 in 2025, then soared by 257.65% to $924217.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $924217.0, -$586229.0, and $604895.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | - |
| 10 | Enveric Biosciences | 5.72 Mn | -2.57 Mn | - | 1.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 924,217.00 |
| Mar 31, 2026 | 924,217.00 |
| Dec 31, 2025 | -586,229.00 |
| Dec 31, 2025 | -586,229.00 |
| Sep 30, 2025 | 604,895.00 |
| Sep 30, 2025 | 604,895.00 |
| Jun 30, 2025 | 205,846.00 |
| Jun 30, 2025 | 205,846.00 |
| Mar 31, 2025 | 874.00 |
| Mar 31, 2025 | 874.00 |
| Dec 31, 2024 | 379,377.00 |
| Dec 31, 2024 | 379,377.00 |
| Sep 30, 2024 | 369,200.00 |
| Sep 30, 2024 | 369,200.00 |
| Jun 30, 2024 | 369,200.00 |
| Jun 30, 2024 | 369,200.00 |
| Mar 31, 2024 | 351,488.00 |
| Mar 31, 2024 | 351,488.00 |
| Dec 31, 2023 | 364,728.00 |
| Dec 31, 2023 | 364,728.00 |